Albert Fleury III
Founder at Cordex Systems
Washington, District of Columbia, United States
Find your path to Albert
481 people in our graph can introduce you to Albert.
Sign up to see every warm intro you have to Albert
- Paths you didn't know you had: your email and LinkedIn already hold routes to Albert. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
About
Albert Fleury III is VP, BioPartnering at Caris Life Sciences and a member of the DMV Angel Group. His background includes finance, economics, and molecular biology, with experience across healthcare, diagnostic, and therapeutic sectors at both US and multinational companies. He has led teams on over $500M in M&A transactions and planned and executed two equity offerings totaling $557M and $97M.
Experience
- DMV Angel GroupMembercurrent2022 — presentWashington DC-Baltimore Area
- Caris Life SciencesVice President - BioPartnering Lead2025 — 2026Irving, TX
- Cellphire Therapeutics, Inc.VP, Cryopreserved Platelets & Capital Support2022 — 2025Rockville, MD
- Cordex Systems, IncPresident, COO and CFO2014 — 2022
- Fairfax PartnersAssociate2013 — 2014Washington DC
- QIAGENDirector - Corporate Finance and Investor Relations; Business Development2007 — 2012
- Digene CorporationInvestor Relations2001 — 2007
Skills & more
Business Process ImprovementOperational StrategyGrowth InitiativesStartup EnvironmentsInvestmentsInvestor RelationsHealthcareMolecular BiologyMedical DiagnosticsManagement ConsultingFinancial AnalysisFinancial Modeling
+10 more
ValuationBusiness ValuationStrategic CommunicationsMergers & AcquisitionsStrategic PartnershipsCorporate FinanceStrategic PlanningManagementStrategyCorporate ValuationsFrom Albert's professional profile.
Frequently asked questions
- Who is Albert Fleury III?
- Albert Fleury III is VP, BioPartnering at Caris Life Sciences and a member of the DMV Angel Group. His background includes finance, economics, and molecular biology, with experience across healthcare, diagnostic, and therapeutic sectors at both US and multinational companies. He has led teams on over $500M in M&A transactions and planned and executed two equity offerings totaling $557M and $97M.
- Where did Albert Fleury III go to school?
- Albert Fleury III studied at The Wharton School (MBA, Finance); Duke University (BS, Dual major: Economics / Molecular Biology).
Same school
Also attended The Wharton School2,000
Sarah GuoFounder & General Partner of ConvictionJosh KopelmanFounder and Partner at First Round CapitalAydin SenkutFounder & Managing Partner at FelicisJack AbrahamFounder, CEO & Managing Partner of AtomicKatie RiesterPartner, Head of Investor Relations at Felicis VenturesRebecca JamesInvestor at Index Ventures
+ 1,994 more
Also attended Duke University1,026
Fred EhrsamCo-founder and Senior Advisor at Paradigm; founder of NudgeJeremy LevinePartner at Bessemer Venture PartnersZach PerretCo-founder & CEO of Plaid; co-founder of MischiefJulie YangVice President at InvestcorpAyaan PatelInvestor at LightbankScott RaneyManaging Director at Redpoint Ventures
+ 1,020 more
Shared employers
Also worked at Caris Life Sciences8
Mark R. JelleyPartner at OrbiMedHarry SkigisFounder at Flat2VRMelissa ToscaChief Financial Officer at Kiora PharmaceuticalsWilliam E. McLaughlinDirector at Fuse MedicalPhillip StaffordChief Data Officer at ACES DiagnosticsJohn QuackenbushExecutive Officer, Director at GenoSpace
+ 2 more
Also worked at Cellphire Therapeutics, Inc.4
Also worked at QIAGEN19
Byron HewettExecutives in Residence at GENERAL INCEPTIONBrad CrutchfieldExecutives in Residence at GENERAL INCEPTIONDavid WelchInvestor at Synthesis CapitalNikhita MistrySustainability Manager at PalatineUplaksh KumarVenture Partner at Foresite CapitalOriana Papin-ZoghbiChief Executive Officer & Co-Founder at AOA Dx
+ 13 more



























